CU6 Stock Overview
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
Notes are coming soon
Clarity Pharmaceuticals Ltd Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.84|
|52 Week High||AU$1.05|
|52 Week Low||AU$0.36|
|1 Month Change||-15.15%|
|3 Month Change||21.74%|
|1 Year Change||14.29%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-44.00%|
Recent News & Updates
|CU6||AU Pharmaceuticals||AU Market|
Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned -25.2% over the past year.
Return vs Market: CU6 exceeded the Australian Market which returned 3.5% over the past year.
|CU6 Average Weekly Movement||9.1%|
|Pharmaceuticals Industry Average Movement||9.7%|
|Market Average Movement||8.5%|
|10% most volatile stocks in AU Market||15.7%|
|10% least volatile stocks in AU Market||3.5%|
Stable Share Price: CU6 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CU6's weekly volatility (9%) has been stable over the past year.
About the Company
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.
Clarity Pharmaceuticals Ltd Fundamentals Summary
|CU6 fundamental statistics|
Is CU6 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CU6 income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.091|
|Net Profit Margin||-367.78%|
How did CU6 perform over the long term?See historical performance and comparison